March 19, 2021

Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia

Category: Article Summary

Topic: Testing and Treatment

Keywords (Tags): treatment

• A multicenter randomized open-labeled clinical trial found that adding Favipiravir to the treatment protocol for in patients with moderate to severe SARS-CoV-2 infection did not reduce the number of ICU admissions or intubations or In-hospital mortality compared to Lopinavir/Ritonavir regimen. It also did not shorten time to clinical recovery or length of hospital stay.

Solaymani-Dodaran et al. Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2021.107522